SLC5A2 and type 2 diabetes mellitus: Results from the EMPA-REG OUTCOME [15] and CANVAS [16] randomised controlled trials and the CVD-REAL observational studies [17–19] have shown a reduced risk for major adverse cardiovascular events, hospitalisation for heart failure or death in patients with T2D treated with SGLT-2 inhibitors, with additional studies ongoing [20].